Michelle Shayne, M.D.

Contact Information

Phone Numbers

Appointment: (585) 486-0600

Administrative: (585) 486-0557

Office: (585) 275-2778

A member of the University of Rochester Medical Faculty Group

An Accountable Health Partner

Accepting New Patients

Locations

125 Red Creek Dr, Ste 211
Calkins Corp Pk, Pluta Cancer Ctr
Rochester, NY 14623-4262

Oncology: (585) 487-1700

Faculty Appointments

Associate Professor - Department of Medicine , Hematology/Oncology (SMD)

Patient Care Setting

Cancer

Biography

Dr. Shayne is Associate Professor of Medicine in Hematology/Oncology at the University of Rochester Medical Center. She obtained her bachelor's degree from the Eastman School of Music and master's degree from the Julliard School before returning to the University of Rochester to obtain her medical degree. She remained at Strong Memorial Hospital for her internship and residency in Internal Medicine. She then completed her oncology fellowship training at Harvard's Beth Israel Deaconess Medical Center in Boston, Mass. She is in clinical practice at Comprehensive Breast Care at Pluta. In addition, she is the Director of the Hereditary Cancer Screening and Risk Reduction Clinic at Wilmot Cancer Institute. Her research interests include the study of chemotherapy-related toxicity in older cancer patients, and survivorship.

Professional Background

Michelle Shayne, MD, FACP is Associate Professor of Medicine and Oncology in the Division of Hematology/Oncology at the Wilmot Cancer Institute of the University of Rochester Medical Center. Dr. Shayne received her medical training at the University of Rochester School of Medicine and Dentistry and at the Beth Israel-Deaconess Medical Center, Harvard Medical School in Boston, Massachusetts. Dr. Shayne's clinical and research interests are in breast cancer, cancer genetics, and survivorship. She is the Clinical Co-Director of the Judy DiMarzo Survivorship Program and she directs the Hereditary Cancer Screening and Risk Reduction Clinic, both at the Wilmot Cancer Institute.

Credentials

Specialties

Internal Medicine
Medical Oncology - American Board of Internal Medicine

Education

1998
MD | University of Rochester School of Medicine & Dentistry

Post-doctoral Training & Residency

07/01/2001 - 06/30/2004
Fellowship in Hematology/Oncology at Beth Israel Deaconess Medical Center

07/01/1999 - 06/30/2001
Residency in Internal Medicine at University of Rochester Medical Center

07/01/1998 - 06/30/1999
Internship in Internal Medicine at University of Rochester Medical Center

VIEW ALL

Awards

2013 - 2015
Marshall Lichtman Dean's Teaching Fellow
Sponsor: University of Rochester Medical Center

2012
Faculty Development Award
Sponsor: University of Rochester Medical Center

2012
Patient-and Family-Centered Care Award
Sponsor: University of Rochester Medical Center

2009 - 2012
Expert Panelist- Weight-Based Dosing Chemotherapy for Cancer Patients Guideline
Sponsor: ASCO

2008 - 2010
Lawrence A. Kohn Senior Teaching Fellow
Location: Rochester, NY

2006
Honored by 3rd year residents in Medicine & Medicine-Pediatrics as faculty member they felt contributed most to education.
Sponsor: University of Rochester Medical Center

1995
Robert I. Weed Summer Research Fellowship in Hematology
Sponsor: University of Rochester School of Medicine and Dentistry
Location: Rochester, NY

VIEW ALL

Clinical Trials

CBRS17061: EA1131: Testing platinum-based chemotherapy after surgery in triple-negative breast cancers,CBRS17061: EA1131: Testing platinum-based chemotherapy after surgery in triple-negative breast cancers

Lead Researcher: Michelle Shayne MD

This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.

View Study Details

Publications

Journal Articles

10/2020
Chowdhry AK, Chowdhry DN, Shayne M, Milano MT. "Second primary breast cancer after diagnosis of breast cancer among male patients: An examination of population characteristics and overall survival." . 2020 Oct 0; 27:100551. Epub 2020 Sep 20.

6/14/2019
Turner BM, Gimenez-Sanders MA, Soukiazian A, Breaux AC, Skinner K, Shayne M, Soukiazian N, Ling M, Hicks DG. "Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX recurrence score <26." Cancer medicine. 2019 Jun 14; Epub 2019 Jun 14.

3/30/2019
Peoples AR, Culakova E, Heckler CE, Shayne M, O'Connor TL, Kirshner JJ, Bushunow PW, Morrow GR, Roscoe JA. "Positive effects of acupressure bands combined with relaxation music/instructions on patients most at risk for chemotherapy-induced nausea." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.. 2019 Mar 30; Epub 2019 Mar 30.

Books & Chapters

2009
Chapter Title: Special considerations - The Hematopoietic Growth Factors in the Elderly
Book Title: Hematopoietic Growth Factors in Oncology
Author List: Shayne M, Balducci L
Published By: Springer 2009

2009
Chapter Title: Breast Cancer Management in the Older Patient
Book Title: Practical Geriatric Oncology
Author List: Shayne M, Kimmick G
Published By: Cambridge University Press 2009

2008
Chapter Title: Supportive Care of the Elderly Cancer Patient
Book Title: Cancer Supportive Care: Advances in Therapeutic Strategies
Author List: Shayne M, Balducci L
Edited By: Lyman G, Crawford J
Published By: Informa Healthcare 2008 in New York, NY

VIEW ALL PUBLICATIONS

Videos

Breast Cancer Awareness